Mecasermin is recombinant human insulin-like growth factor-1 (IGF-1): a 70-amino-acid chain held in shape by three disulfide bridges. It replaces the growth signal that growth hormone normally triggers. This guide covers its structure, mechanism, FDA-labeled use, key studies and label warnings. Sources were checked on November 17, 2026.
Quick answer: Mecasermin is a prescription form of IGF-1 sold as Increlex. Its label covers growth failure in children aged 2 and older with severe primary IGF-1 deficiency. It also covers children with a GH gene deletion and neutralizing antibodies to GH. It is not a substitute for growth hormone. Low blood sugar is its main warning; there is no boxed warning.
Vitrapep does not sell mecasermin; this page is a reference summary of published research and regulatory information.
What is mecasermin?
Mecasermin is human IGF-1 made by recombinant DNA technology in modified E. coli bacteria. The Increlex label describes a single chain of 70 amino acids with three internal disulfide bridges and a molecular weight of 7,649 Da. It states: “The amino acid sequence of the product is identical to that of endogenous human IGF-1” (Increlex label, 2025).
Is it a peptide? Yes in the chemical sense: it is a single amino acid chain, a polypeptide. At 70 amino acids, though, it passes FDA’s cutoff for a protein. Federal rules define a protein as a polymer “greater than 40 amino acids in size” (21 CFR 600.3). See our peptide vs protein explainer. PubChem has no compound record for mecasermin, so no molecular formula is given here.
Drugs@FDA lists the original approval of Increlex on August 30, 2005, with Ipsen as the company. The record notes: “This Former NDA Was Deemed To Be a BLA on March 23, 2020” (Drugs@FDA). DailyMed now lists Eton Pharmaceuticals as a labeler for Increlex.
Mecasermin: key facts
| Fact | Detail |
|---|---|
| Structure type | Single-chain polypeptide of 70 amino acids with three disulfide bridges |
| Class | Recombinant human insulin-like growth factor-1 (biologic) |
| Molecular formula | No PubChem compound record; label describes it by amino acid count |
| Molecular weight | 7,649 Da (Increlex label) |
| First FDA approval | August 30, 2005 (Increlex, BLA 021839, originally an NDA) |
| Brand names (US) | Increlex |
How does mecasermin work?
Normal growth runs through a two-step chain. Growth hormone (GH) binds its receptor in the liver and other tissues, and those tissues make IGF-1. IGF-1 then activates the type 1 IGF-1 receptor in target tissues, and that signaling drives growth. The Increlex label calls IGF-1 “a key hormonal mediator on statural growth” (Increlex label, 2025).
In primary IGF-1 deficiency, the first step fails. GH levels are normal or high, but the body does not make enough IGF-1. Extra GH cannot fix that, so mecasermin supplies IGF-1 directly. That is the opposite situation to GH deficiency, where somatropin is used. IGF-1 also acts on glucose. The label says IGF-1 “suppresses hepatic glucose production and stimulates peripheral glucose utilization” (Increlex label, Ipsen, 2025).
What is mecasermin approved for?
The Increlex label covers growth failure in pediatric patients aged 2 years and older with either:
- severe primary IGF-1 deficiency, defined by height and basal IGF-1 standard deviation scores of −3.0 or lower with normal or elevated GH; or
- a GH gene deletion, in patients who have developed neutralizing antibodies to GH.
The label sets limits too. Increlex is not a substitute for GH in approved GH indications. It is not indicated for secondary IGF-1 deficiency, such as deficiency caused by GH deficiency, malnutrition or hypothyroidism.
What did the key trials show?
Severe primary IGF-1 deficiency. The label pools five human studies in 71 children with severe primary IGF-1 deficiency. Four were open-label, and one was double-blind and placebo-controlled. Of these, 61 had at least one year of data. Their mean height velocity rose from 2.8 cm per year before treatment to 8.0 cm per year in year 1. The gain shrank over time, to 0.7 cm per year above baseline by year 8. It was no longer statistically significant in years 7 and 8 (Increlex label, 2025).
A long-term report on 76 children with severe IGF-1 deficiency due to GH insensitivity matches these figures. It found height velocity of 2.8 cm per year at baseline and 8.0 cm per year in the first year. Later-year velocities stayed above baseline for up to 8 years (Chernausek et al., 2007).
Short children with low IGF-1. A one-year randomized, open-label human trial enrolled 136 short, prepubertal children with low IGF-1 levels at 30 U.S. clinics. Of these, 111 were treated and 25 were observed without treatment. First-year height velocity was 7.0 and 7.9 cm per year in the two treated groups. It was 5.2 cm per year in the untreated group (Midyett et al., 2010). The study, coded MS301, is registered as NCT00125164.
What side effects does the label list?
The Increlex label has no boxed warning. Its highlights name hypoglycemia, local and systemic hypersensitivity and tonsillar hypertrophy as common reactions. In the clinical studies, 30 of 71 subjects (42%) had hypoglycemia at least once. Tonsillar hypertrophy was reported in 11 subjects (15%).
The label’s warnings cover hypoglycemia, allergic reactions including anaphylaxis, and raised pressure in the skull. They also cover enlarged lymphoid tissue such as tonsils, slipped capital femoral epiphysis and worsening scoliosis. Malignant neoplasia is a warning and a contraindication. A further warning concerns benzyl alcohol in the solution and serious reactions in infants. Closed growth plates and known hypersensitivity are also contraindications (Increlex label, 2025).
What is mecasermin’s regulatory status, and how is it used in research?
Mecasermin is a prescription biologic in the United States. Its original NDA was deemed a biologics license application on March 23, 2020. DailyMed lists Increlex labels from Eton Pharmaceuticals and Ipsen Biopharmaceuticals (DailyMed, 2026). Ipsen also ran an observational registry to track long-term safety and efficacy. It enrolled 1,378 patients and is listed as terminated (NCT00747604). The research summarized here is clinical: human studies in children with growth failure.
Frequently asked questions about mecasermin
Is mecasermin a peptide?
It is a 70-amino-acid polypeptide. Because it has more than 40 amino acids, FDA rules class it as a protein.
Is mecasermin the same as IGF-1?
Yes. The label says its amino acid sequence is identical to that of endogenous human IGF-1.
How is mecasermin different from somatropin?
Somatropin is growth hormone, which tells the body to make IGF-1. Mecasermin is IGF-1 itself. The label says it is not a substitute for GH in GH indications.
When was mecasermin approved?
Drugs@FDA lists the original approval of Increlex on August 30, 2005.
Why does mecasermin cause low blood sugar?
The label states that Increlex “has insulin-like hypoglycemic effects.” Hypoglycemia is its first warning, and 42% of study subjects had at least one episode.
What to know now
- Structure: 70-amino-acid recombinant human IGF-1 with three disulfide bridges; 7,649 Da.
- Approval: Increlex, August 30, 2005; deemed a biologic in 2020; prescription only.
- Mechanism: supplies IGF-1 directly, bypassing the GH step.
- Use: severe primary IGF-1 deficiency or GH gene deletion with neutralizing antibodies.
- Evidence: height velocity rose from 2.8 to 8.0 cm per year in year 1, with gains fading later.
- Safety: no boxed warning; hypoglycemia in 42% and tonsillar hypertrophy in 15%.
What we’re watching
Further Increlex label revisions on DailyMed; the Eton label was last revised in October 2025. Related guides: somatropin, pegvisomant and insulin analogs.